C41 LONG ACTING BRONCHODILATOR THERAPY IN COPD II: Effect Of Treatment Withdrawal On Outcomes In The Summit Study

Jorgen.Vestbo@manchester.ac.uk Rationale: To date, no studies have adequately examined the withdrawal of long-acting bronchodilators (LABD) or inhaled corticosteroids (ICS) on patient outcomes despite the potential implications for both clinical practice and the design of clinical trials. The SUMMIT...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Main Authors: Vestbo, J, Anderson, J A, Brook, R D, Calverley, P MA, Celli, B, Crim, C C, Dransfield, M T, Gallot, N S, Kilbride, S, Lange, P, Martinez, F J, Newby, D E, Yates, J C
Format: Article
Language:English
Subjects:
Chronic obstructive pulmonary disease
Health risk assessment
Mortality
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Jorgen.Vestbo@manchester.ac.uk Rationale: To date, no studies have adequately examined the withdrawal of long-acting bronchodilators (LABD) or inhaled corticosteroids (ICS) on patient outcomes despite the potential implications for both clinical practice and the design of clinical trials. The SUMMIT trial provides a unique opportunity to examine the impact of prior medication use and withdrawal on the risk of mortality and COPD exacerbations after randomization.
ISSN:1073-449X
1535-4970